Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00557505 · ClinicalTrials.gov registry record · Phase 1

A Study Of PF-03732010 In Patients With Advanced Solid Tumors

A Phase 1 study of Neoplasms, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
43
Enrollment target
3
Study locations

NCT00557505 is a Phase 1 study of Neoplasms that has completed, run by Pfizer. The registered enrollment target is 43 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00557505, a Phase 1 study of Neoplasms, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
43 participants
Enrollment target
3
Study locations

Study Summary

P-cadherin may play a part in tumor growth; PF-03732010 is a new drug that inhibits P-cadherin. This study will test how well the drug is tolerated, and what effects there might be. Blood will also be taken to measure the amount of drug in blood.

Conditions Studied

Neoplasms

Interventions

  • DRUG PF-03732010

Study Locations (3)

Pennsylvania

  • Pfizer Investigational Site - Philadelphia

Victoria

  • Pfizer Investigational Site - Parkville

Other

  • Pfizer Investigational Site - Seoul

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2007-12
Est. Completion 2011-02
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00557505

The ClinicalTrials.gov registry entry for NCT00557505 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which PF-03732010 is the first listed.

NCT00557505 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Pennsylvania, Victoria, Other.

Frequently Asked Questions

What is clinical trial NCT00557505 about?

NCT00557505 is a clinical study titled "A Study Of PF-03732010 In Patients With Advanced Solid Tumors". P-cadherin may play a part in tumor growth; PF-03732010 is a new drug that inhibits P-cadherin. This study will test how well the drug is tolerated, and what effects there might be. Blood will also be taken to measure the amount of drug in blood.

What is the current status of trial NCT00557505?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2007-12. Estimated completion is 2011-02.

What conditions does trial NCT00557505 study?

This clinical trial studies the following conditions: Neoplasms.

What interventions are being tested in trial NCT00557505?

The interventions under investigation include: PF-03732010 (DRUG).

Who is sponsoring clinical trial NCT00557505?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00557505 being conducted?

This trial has 3 study locations across Pennsylvania, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasms

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.